Alimera Sciences (NASDAQ:ALIM) Downgraded by StockNews.com to "Hold"

Alimera Sciences (NASDAQ:ALIM - Get Free Report) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Friday.

Separately, Maxim Group began coverage on Alimera Sciences in a research note on Monday, March 25th. They set a "buy" rating and a $10.00 price target for the company.

Alimera Sciences Stock Down 8.6 %

Alimera Sciences stock traded down $0.33 during mid-day trading on Friday, hitting $3.52. The company's stock had a trading volume of 56,087 shares, compared to its average volume of 80,829. The firm's 50 day moving average is $3.76 and its 200 day moving average is $3.60. The company has a market cap of $184.29 million, a PE ratio of -1.63 and a beta of 1.18. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.39 and a quick ratio of 2.31. Alimera Sciences has a 52-week low of $1.56 and a 52-week high of $4.38.

Alimera Sciences (NASDAQ:ALIM - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.09). The business had revenue of $26.31 million during the quarter, compared to analysts' expectations of $25.10 million. Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. During the same period in the prior year, the company posted ($0.54) earnings per share. On average, analysts anticipate that Alimera Sciences will post 0.03 earnings per share for the current year.

Institutional Investors Weigh In On Alimera Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. AIGH Capital Management LLC bought a new position in shares of Alimera Sciences in the 3rd quarter valued at approximately $7,355,000. Stonepine Capital Management LLC bought a new position in shares of Alimera Sciences in the 3rd quarter valued at approximately $12,349,000. Worth Venture Partners LLC bought a new position in shares of Alimera Sciences in the 3rd quarter valued at approximately $1,840,000. Balyasny Asset Management L.P. bought a new position in shares of Alimera Sciences in the 4th quarter valued at approximately $173,000. Finally, Geode Capital Management LLC raised its stake in shares of Alimera Sciences by 55.0% in the 2nd quarter. Geode Capital Management LLC now owns 59,324 shares of the biopharmaceutical company's stock valued at $173,000 after acquiring an additional 21,062 shares in the last quarter. 99.83% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.